Skip to main content
Fig. 6 | Infectious Agents and Cancer

Fig. 6

From: Construction and immune effect of an HPV16/18/58 trivalent therapeutic adenovirus vector vaccine

Fig. 6

Specific immune procedures of the treatment model, the full gene of the pGH/HPV16/18/58 mE6E7 plasmid after point mutation, and verification of the recombinant adenovirus shuttle plasmid ADV4-HPV16/18/58 mE6E7. A Specific immune procedures of the treatment model. B the PCR results of the HPV16, 18, and 58 mE6E7 gene fragments, M: DNA marker (50 bp), A: HPV16 mE6E7 fusion gene (768 bp), B: HPV18 mE6E7 fusion gene (789 bp), C: HPV58 mE6E7 fusion gene (741 bp). C The restriction results of the HPV16/18/58 mE6E7 fusion gene fragments, and the sequencing results of the plasmid pGH-HPV16/18/58 mE6E7. M: DNA marker (5000 bp), A: plasmid pGH-HPV16/18/58 mE6E7, B, C, D: plasmid pGH-HPV16/18/58 mE6E7 after digestion. D Sequencing results of the plasmid pGH-HPV16/18/58 mE6E7. E The results of double enzyme digestion of plasmid ADV4-HPV16/18/58 mE6E7. M: DNA markers 1, 2, 3, 4, and 5: Successfully constructed recombinant shuttle plasmid ADV4-HPV16/18/58 mE6E7 (3480 bp). F The sequencing results and peak spectrum of the recombinant adenovirus shuttle plasmid ADV4-HPV16/18/58 mE6E7

Back to article page